ERYTECH Pharma S.A.
ERYP
Price:
$0.78
Market Cap:
$42.61M
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.[Read more]
Industry
Biotechnology
IPO Date
2016-07-05
Stock Exchange
NASDAQ
Ticker
ERYP
The ROE as of September 2024 (TTM) for ERYTECH Pharma S.A. (ERYP) is 6.80%
According to ERYTECH Pharma S.A.’s latest financial reports and current stock price. The company's current ROE is 6.80%. This represents a change of -63.17% compared to the average of 18.45% of the last 4 quarters.
ERYTECH Pharma S.A. (ERYP) Historical ROE (quarterly & annually)
How has ERYP ROE performed in the past?
The mean historical ROE of ERYTECH Pharma S.A. over the last ten years is -80.86%. The current 6.80% ROE has changed -108.40% with respect to the historical average. Over the past ten years (40 quarters), ERYP's ROE was at its highest in in the June 2022 quarter at 48.52%. The ROE was at its lowest in in the December 2020 quarter at -74.41%.
Average
-80.86%
Median
-45.90%
Minimum
-276.20%
Maximum
-0.97%
ERYTECH Pharma S.A. (ERYP) ROE by Quarter and Year
Discovering the peaks and valleys of ERYTECH Pharma S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 277.14%
Maximum Annual ROE = -0.97%
Minimum Annual Increase = -211.14%
Minimum Annual ROE = -276.20%
| Year | ROE | Change |
|---|---|---|
| 2022 | -0.97% | -99.59% |
| 2021 | -235.49% | -14.74% |
| 2020 | -276.20% | 277.14% |
| 2019 | -73.23% | 178.97% |
| 2018 | -26.25% | 42.04% |
| 2017 | -18.48% | -69.94% |
| 2016 | -61.49% | 93.04% |
| 2015 | -31.85% | 28.79% |
| 2014 | -24.73% | -58.74% |
| 2013 | -59.95% | -211.14% |
ERYTECH Pharma S.A. (ERYP) Average ROE
How has ERYP ROE performed in the past?
The current ROE of ERYTECH Pharma S.A. (ERYP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-170.89%
5-year avg
-122.43%
10-year avg
-80.86%
ERYTECH Pharma S.A. (ERYP) ROE vs. Peers
How is ERYP’s ROE compared to its peers?
ERYTECH Pharma S.A.’s ROE is greater than Genfit S.A. (-60.96%), greater than Cyteir Therapeutics, Inc. (-23.13%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than HCW Biologics Inc. (-385.90%), greater than Aptorum Group Limited (-12.10%), greater than Surrozen, Inc. (-178.66%), less than Unicycive Therapeutics, Inc. (294.74%), less than Armata Pharmaceuticals, Inc. (182.35%), greater than Addex Therapeutics Ltd (-456.73%), greater than Aceragen, Inc. (-46.48%), greater than Soligenix, Inc. (-256.63%), greater than Avenue Therapeutics, Inc. (-749.10%), less than Molecular Partners AG (0%), greater than XORTX Therapeutics Inc. (-33.08%), greater than Nutriband Inc. (-36.97%), greater than Ikena Oncology, Inc. (-76.31%), greater than Enochian Biosciences, Inc. (-42.81%), greater than Exicure, Inc. (-70.62%), greater than null (-288.03%),
| Company | ROE | Market cap |
|---|---|---|
| -60.96% | $205.89M | |
| -23.13% | $108.71M | |
| -47.03% | $550.56M | |
| -385.90% | $22.69M | |
| -12.10% | $14.56M | |
| -178.66% | $27.92M | |
| 294.74% | $35.68M | |
| 182.35% | $79.60M | |
| -456.73% | $15.88M | |
| -46.48% | $3.24M | |
| -256.63% | $8.23M | |
| -749.10% | $3.91M | |
| 0% | $172.94M | |
| -33.08% | $5.26M | |
| -36.97% | $51.93M | |
| -76.31% | $83.00M | |
| -42.81% | $45.38M | |
| -70.62% | $3.69M | |
| -288.03% | $0 |
Build a custom stock screener for ERYTECH Pharma S.A. (ERYP) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ERYTECH Pharma S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
ERYTECH Pharma S.A. (ERYP) and other stocks custom spreadsheet templates
The easiest way to analyze a company like ERYTECH Pharma S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is ERYTECH Pharma S.A.'s ROE?
How is the ROE calculated for ERYTECH Pharma S.A. (ERYP)?
What is the highest ROE for ERYTECH Pharma S.A. (ERYP)?
What is the 3-year average ROE for ERYTECH Pharma S.A. (ERYP)?
What is the 5-year average ROE for ERYTECH Pharma S.A. (ERYP)?
How does the current ROE for ERYTECH Pharma S.A. (ERYP) compare to its historical average?